Displaying drugs 626 - 650 of 15212 in total
Dexchlorpheniramine maleate
Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
Approved
Matched Iupac: … (2Z)-but-2-enedioic acid; [(3S)-3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine …
Matched Description: … Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic …
Matched Mixtures name: … Chlophedianol Hydrochloride, Dexchlorpheniramine Maleate, and Pseudoephedrine Hydrochloride …
Matched Description: … Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic …
Matched Mixtures name: … Chlophedianol Hydrochloride, Dexchlorpheniramine Maleate, and Pseudoephedrine Hydrochloride …
Daprodustat
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.[A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces...
Approved
Investigational
Matched Iupac: … 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinan-5-yl)formamido]acetic acid …
Matched Description: … HIF1α and HIF2α and the induces erythropoiesis. ... As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular ... [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Matched Description: … HIF1α and HIF2α and the induces erythropoiesis. ... As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular ... [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Sorghum halepense pollen
Sorghum halepense pollen is the pollen of the Sorghum halepense plant. Sorghum halepense pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Mixture of Standardized and Non-Standardized Southern Grasses ... Mixture of Twenty-Two Standardized and Non-Standardized Grasses …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Iupac: … 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid …
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Ritiometan
Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.
Approved
Matched Iupac: … 2-({bis[(carboxymethyl)sulfanyl]methyl}sulfanyl)acetic acid …
Propiolactone
Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. It is currently...
Approved
Withdrawn
Matched Description: … It has been used against bacteria, fungi, and virus. ... disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and …
Crisaborole
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … reducing the signs and symptoms in patients 2 years old and older. ... It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a ... This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and …
Ethyl ferulate
Approved
Experimental
Tezacaftor
Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … consequently abnormal fluid and ion transport across cell membranes. ... [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and …
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …
Levomilnacipran
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is ... [A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does ... [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …
Pegunigalsidase alfa
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … allowing it to reach target organs with a lower dose and frequency of administration. ... [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and ... While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Aflibercept
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It...
Approved
Matched Description: … exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues ... it was approved by the FDA and EMA in August 2012 and February 2013, respectively. ... composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Estradiol acetate
Estradiol acetate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Description: … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary ... a chance to enter systemic circulation and exert its estrogenic effects [A12102]. ... Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex …
Estradiol cypionate
Estradiol Cypionate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol cypionate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Description: … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary ... skin, prostate, bone, fat, and brain. ... a chance to enter systemic circulation and exert its estrogenic effects [A12102]. …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Pascopyrum smithii pollen
Pascopyrum smithii pollen is the pollen of the Pascopyrum smithii plant. Pascopyrum smithii pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Mixture of Twenty-Two Standardized and Non-Standardized Grasses …
Susoctocog alfa
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … B domain replaced with a twenty-four amino acid linker. ... These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for …
Matched Categories: … Blood and Blood Forming Organs …
Matched Categories: … Blood and Blood Forming Organs …
Torasemide
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved
Lifitegrast
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Iupac: … carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6-yl]formamido}-3-(3-methanesulfonylphenyl)propanoic acid …
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Betiatide
Approved
Experimental
Matched Iupac: … 2-(2-{2-[2-(benzoylsulfanyl)acetamido]acetamido}acetamido)acetic acid …
Nirsevimab
Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … neutralizes several RSV A and B strains. ... antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and ... the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Iodohippurate sodium I-131
Approved
Niraparib
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …
Methacholine
Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing symptoms such as difficulty breathing.[A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can...
Approved
Investigational
Matched Description: … muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and ... [A229648, L31763]
Methacholine was granted FDA approval on October 31, 1986, and is marketed under …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Displaying drugs 626 - 650 of 15212 in total